{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T11:40:40Z","timestamp":1771587640042,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>More than 40 tyrosine kinase inhibitors (TKIs) have received hematological or oncological indications over the past 20 years, following the approval of imatinib, and many others are currently being tested in clinical and preclinical level. Beyond their common toxicities, no certain agent from this large class of molecularly targeted therapies was strongly associated with \u201coff-target\u201d impairment of neuromuscular transmission, and although myasthenia gravis (MG) is a well-characterized autoimmune disorder, only few sporadic events proven by serologically detected causative autoantibodies and\/or by positive electrophysiological tests are reported in the literature. Herein, we present the first case of anti-MUSK (+) MG in a woman with metastatic BRAF-mutant melanoma after long-term treatment with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor). Triggered by this report, a systematic literature review was conducted, summarizing all other cancer cases that developed MG, after exposure to any type of targeted agent and regardless of the underlying malignancy. All available data on the clinical diagnosis, the potential of administered TKIs to induce a seropositive myasthenic syndrome, the immune and non-immune-mediated pathogenesis of postsynaptic damage, and the challenging management of this neuromuscular toxicity were collected and discussed. In the presented case, MG was confirmed by both autoantibodies and nerve-conduction tests, while its reactivation after TKIs rechallenge supports a more than coincidental association. The following review identified 12 cancer cases with TKI-related MG in six case reports and one case series. In most of them, the myasthenia diagnosis was challenging, since the clinical symptomatology of fatigable weakness was not corroborating with consistent laboratory and electrophysiological findings. In fact, anti-AchR titers were positive in five and anti-MuSK only in the abovementioned individual. The symptomatology corresponded to TKI discontinuation and standard treatment with pyridostigmine and prednisolone; intravenous immunoglobulin was added only in three, and two required mechanical ventilation. In an era where TKIs will be prescribed more frequently for various malignancies, even in combinations with immune-checkpoint inhibitors, this report synthesizes their risk for neuromuscular complications and increases the clinicians\u2019 awareness in order to extend the on-treatment and overall survival of TKI-treated cancer patients.<\/jats:p>","DOI":"10.3389\/fonc.2021.727010","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T01:13:23Z","timestamp":1634346803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review"],"prefix":"10.3389","volume":"11","author":[{"given":"Dimitrios C.","family":"Ziogas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Mandellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos","family":"Theocharopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis-Petros","family":"Lialios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Bouros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314173","article-title":"Thymectomy in the Treatment of Myasthenia Gravis: Report of 247 Patients","volume":"235","author":"Evoli","year":"1988","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.05.011","article-title":"Anti-MuSK- and Anti-AChR-Positive Myasthenia Gravis Induced by D-Penicillamine","volume":"250","author":"Poulas","year":"2012","journal-title":"J Neuroimmunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.005","article-title":"Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies","volume":"16","author":"Sechi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular Adverse Events Associated With Anti-PD-1 Monoclonal Antibodies: Systematic Review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071537","article-title":"Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting Cancer With Small Molecule Kinase Inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13096","article-title":"Ten Things You Should Know About Protein Kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/138161212800672813","article-title":"New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr Pharm Des"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-Targeted Cancer Therapies: Progress, Challenges and Future Directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A 2020 Update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008860","article-title":"Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma","volume":"94","author":"Zaloum","year":"2020","journal-title":"Neurology"},{"key":"B16","first-page":"1291","article-title":"An Unprecedented Case of Myasthenia Gravis Induced by Binimetinib","volume":"9","author":"Alabdali","year":"2019","journal-title":"J Clin Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04604-1","article-title":"Neuromuscular Complications Following Targeted Therapy in Cancer Patients: Beyond the Immune Checkpoint Inhibitors. Case Reports and Review of the Literature","volume":"42","author":"Demichelis","year":"2021","journal-title":"Neurol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bjh.15557","article-title":"Myasthenia Gravis Unmasked by Imatinib","volume":"184","author":"Kopp","year":"2019","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.4081\/hr.2014.5288","article-title":"Development of Myasthenia Gravis in a Patient With Chronic Myeloid Leukemia During Treatment With Nilotinib","volume":"6","author":"Sanford","year":"2014","journal-title":"Hematol Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182074a69","article-title":"Neuromuscular Junction Toxicity With Tandutinib Induces a Myasthenic-Like Syndrome","volume":"76","author":"Lehky","year":"2011","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.06.024","article-title":"New Onset Myasthenia Gravis in a Patient With non Small Cell Lung Cancer Treated With Lorlatinib a Novel Anti-Cancer Agent","volume":"392","author":"Desai","year":"2018","journal-title":"J Neurol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26390","article-title":"Repetitive Nerve Stimulation Test in Myasthenic Crisis","volume":"59","author":"Oh","year":"2019","journal-title":"Muscle Nerve"},{"key":"B23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B24","article-title":"Multiple Cranial Neuropathy and Myasthenic Syndrome Secondary to Nilotinib","volume":"20","author":"Gundin","year":"2018","journal-title":"Eur J Clin Pharm"},{"key":"B25","volume-title":"Medications and Myasthenia Gravis (A Reference for Health Care Professionals)","author":"Mehrizi","year":"2012"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 Clinical Results With Tandutinib (MLN518), a Novel FLT3 Antagonist, in Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome: Safety, Pharmacokinetics, and Pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2010.10.008","article-title":"Muscle Specific Kinase: Organiser of Synaptic Membrane Domains","volume":"43","author":"Ghazanfari","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of Collagen-Induced Discoidin Domain Receptor 1 and 2 Activation by Imatinib, Nilotinib and Dasatinib","volume":"599","author":"Day","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 Autoantibodies Cause Myasthenia Gravis by Inhibiting Binding Between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory Effects of BRAF and MEK Inhibitors: Implications for Melanoma Therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T Cells in Multiple Sclerosis and Myasthenia Gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-Associated Molecules on CD4+CD25 +Treg Cells in Myasthenia Gravis and Effects of Immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01018.x","article-title":"Regulatory T Cells and Foxp3","volume":"241","author":"Rudensky","year":"2011","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6294","article-title":"Therapeutic Immune Monitoring of CD4(+)CD25(+) T Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors","volume":"14","author":"Lu","year":"2017","journal-title":"Oncol Lett"},{"key":"B35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-4598-9-22","article-title":"Effects of Nilotinib on Regulatory T Cells: The Dose Matters","volume":"9","author":"Fei","year":"2010","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.10.6955","article-title":"Imatinib Mesylate Inhibits CD4+ CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy Against BCR-ABL- Tumors","volume":"181","author":"Larmonier","year":"2008","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004747","article-title":"IL-2 Regulates FOXP3 Expression in Human CD4+CD25+ Regulatory T Cells Through a STAT-Dependent Mechanism and Induces the Expansion of These Cells In Vivo","volume":"108","author":"Zorn","year":"2006","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101804","article-title":"T Cell-Signaling Network Analysis Reveals Distinct Differences Between CD28 and CD2 Costimulation Responses in Various Subsets and in the MAPK Pathway Between Resting and Activated Regulatory T Cells","volume":"187","author":"Kalland","year":"2011","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12397","article-title":"MEK Inhibition Prevents Tumour-Shed Transforming Growth Factor-Beta-Induced T-Regulatory Cell Augmentation in Tumour Milieu","volume":"144","author":"Hossain","year":"2015","journal-title":"Immunology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0141903","DOI":"10.1371\/journal.pone.0141903","article-title":"Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells With MEK\/ERK Signaling Pathway Inhibitors","volume":"10","author":"Lieske","year":"2015","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine Kinase Inhibitor Imatinib Augments Tumor Immunity by Depleting Effector Regulatory T Cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.012","article-title":"Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool","volume":"41","author":"Vahl","year":"2014","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/leu.2010.11","article-title":"Lck is a Key Target of Imatinib and Dasatinib in T-Cell Activation","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.008","article-title":"Lambert-Eaton Myasthenic Syndrome","volume":"36","author":"Kesner","year":"2018","journal-title":"Neurol Clin"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1102\/1470-5206.2010.0008","article-title":"Myasthenia Gravis Improvement in a Patient Receiving Sunitinib for Metastatic Renal Cell Carcinoma","volume":"10","author":"Lee","year":"2010","journal-title":"Grand Rounds"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm010","article-title":"Chronic Myeloid Leukemia Presenting as Paraneoplastic Ocular Myasthenia Gravis","volume":"18","author":"Kumar","year":"2007","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25458","article-title":"Remission of Myasthenia Gravis With MuSK Antibodies During Ruxolitinib Treatment","volume":"55","author":"Alboini","year":"2017","journal-title":"Muscle Nerve"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in Myasthenia Gravis in the Era of Biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22070","article-title":"Increased Serum Interleukin-17 Levels in Patients With Myasthenia Gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"B50","doi-asserted-by":"publisher","first-page":"25886","DOI":"10.1038\/srep25886","article-title":"Changes in Inflammatory Cytokine Networks in Myasthenia Gravis","volume":"6","author":"Uzawa","year":"2016","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809850105","article-title":"IL-6 Controls Th17 Immunity In Vivo by Inhibiting the Conversion of Conventional T Cells Into Foxp3+ Regulatory T Cells","volume":"105","author":"Korn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial Effect of Tocilizumab in Myasthenia Gravis Refractory to Rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J Neuromuscul Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.727010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T01:13:27Z","timestamp":1634346807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.727010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":53,"alternative-id":["10.3389\/fonc.2021.727010"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.727010","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"article-number":"727010"}}